ITHACA, N.Y.--(BUSINESS WIRE)--Vybion will present data on how its drug, INT41, alters a critical event in the development of Huntington’s disease at the 7th Neurodegenerative Conditions Research & Development Conference in Boston on September 9-10, 2013. INT41 is an Intrabody drug delivered by Gene Therapy that blocks gene dysregulation in Huntington’s Disease by neutralizing a toxic fragment of the Huntingtin mutant protein in the nucleus of the cell preventing gene dysregulation.
Help employers find you! Check out all the jobs and post your resume.
